TEKI yields 2000000.00% · ABBV yields 3.06%● Live data
📍 TEKI pulled ahead of the other in Year 1
Combined, TEKI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TEKI + ABBV for your $10,000?
Tek Digitel Corp. develops equipment that converts analog voice data to a digital format suitable for network transmission using standard Internet Protocols (IP). Its equipment, known as gateway, consists of proprietary computer hardware and software that connects a standard telephone to the Internet or other digital network. The company's Voice over IP (VoIP) technology allows users to transmit all of their voice and fax communications using the Internet, instead of the conventional telephone network. Tek Digitel Corp. focuses on developing customer premise equipment located at the home or office. It targets its products to telecommunications companies that base their telecommunications structure on the Internet by offering Internet connectivity and VoIP as their primary solutions. The company's VoIP gateway devices and V-Server® product line offers services, including local and long-distance voice connectivity; voice features, such as voice mail, unified messaging, and fax transmission, as well as basic Internet data access for multiple users at a single site. The V-Server products are designed for use with a variety of Internet access services, including Integrated Services Digital Networks, Wireless telephones, Digital Subscriber Loops, and Cable modem delivery. The company has also developed personal computer client and server-based provision/management tools to allow the gateway devices to be configured and managed to support the interconnection of users across public Internet or private corporate intranets. The company was formerly known as ATC Group L.L.C. and changed its name to Tek Digitel Corp. in July, 1998. The company is based in Germantown, Maryland.
Full TEKI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.